Keywords: blow, roche, phase, iii, tempium, trials, discontinued
Blow for Roche as Phase III Tempium trials are discontinued
Article | 16 September 1999
Switzerland's Roche says that it has discontinued the development ofTempium (lazabemide), a monoamine oxidase type B inhibitor for Alzheimer's disease, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
